Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Amortizatization of Intangibles: 2021-2024

Historic Amortizatization of Intangibles for 4D Molecular Therapeutics (FDMT) over the last 4 years, with Dec 2024 value amounting to $7.2 million.

  • 4D Molecular Therapeutics' Amortizatization of Intangibles fell 48.48% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year decrease of 5.33%. This contributed to the annual value of $7.2 million for FY2024, which is 364.85% up from last year.
  • According to the latest figures from FY2024, 4D Molecular Therapeutics' Amortizatization of Intangibles is $7.2 million, which was up 364.85% from $1.5 million recorded in FY2023.
  • Over the past 5 years, 4D Molecular Therapeutics' Amortizatization of Intangibles peaked at $7.2 million during FY2024, and registered a low of $1.5 million during FY2022.
  • In the last 3 years, 4D Molecular Therapeutics' Amortizatization of Intangibles had a median value of $1.5 million in 2023 and averaged $3.4 million.
  • Per our database at Business Quant, 4D Molecular Therapeutics' Amortizatization of Intangibles fell by 1.34% in 2022 and then skyrocketed by 364.85% in 2024.
  • 4D Molecular Therapeutics' Amortizatization of Intangibles (Yearly) stood at $1.5 million in 2021, then declined by 1.34% to $1.5 million in 2022, then grew by 4.60% to $1.5 million in 2023, then spiked by 364.85% to $7.2 million in 2024.